These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1643148)

  • 21. Panel approves gene trial for "normals".
    Marshall E
    Science; 1997 Mar; 275(5306):1561. PubMed ID: 9072819
    [No Abstract]   [Full Text] [Related]  

  • 22. US plan to scrap DNA panel splits genetic researchers.
    Wadman M
    Nature; 1996 Jul; 382(6588):197. PubMed ID: 8717029
    [No Abstract]   [Full Text] [Related]  

  • 23. The NIH "Points to Consider" and the limits of human gene therapy.
    Juengst ET
    Hum Gene Ther; 1990; 1(4):425-33. PubMed ID: 2078585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990.
    Anderson WF; Blaese RM; Culver K
    Hum Gene Ther; 1990; 1(3):331-62. PubMed ID: 11642817
    [No Abstract]   [Full Text] [Related]  

  • 25. Scientific and ethical considerations in human gene therapy.
    Lebo RV; Golbus MS
    Baillieres Clin Obstet Gynaecol; 1991 Sep; 5(3):697-713. PubMed ID: 1954734
    [No Abstract]   [Full Text] [Related]  

  • 26. NIH review of gene therapy protocols.
    Varmus H
    Science; 1995 Mar; 267(5206):1889. PubMed ID: 7701310
    [No Abstract]   [Full Text] [Related]  

  • 27. TNF/TIL human gene therapy clinical protocol.
    Hum Gene Ther; 1990; 1(4):441-80. PubMed ID: 2078586
    [No Abstract]   [Full Text] [Related]  

  • 28. Special informed consent requirements are included in protocol review procedures.
    Maloney DM
    Hum Res Rep; 1995 Jul; 10(7):1-2. PubMed ID: 11654274
    [No Abstract]   [Full Text] [Related]  

  • 29. An act...to establish a program of National Research Service Awards...and to provide for the protection of human subjects involved in biomedical and behavioral research.... Approved 12 Jul 1974.
    U.S
    US Statut Large; 1974; 88 342-354():2-354. PubMed ID: 12085916
    [No Abstract]   [Full Text] [Related]  

  • 30. Compassionate exemptions.
    Anderson WF
    Hum Gene Ther; 1993 Apr; 4(2):125-6. PubMed ID: 8494921
    [No Abstract]   [Full Text] [Related]  

  • 31. Half-full or half-empty? Evaluating IRB performance.
    Mishkin B; Ariand N
    Prof Ethics Rep; 1998; 11(3):4-7. PubMed ID: 11657925
    [No Abstract]   [Full Text] [Related]  

  • 32. Protection of human subjects.
    United States
    Code Fed Regul Shipping; 1982 Oct; Part 46, Sections 46.101 to 46.306():. PubMed ID: 11660819
    [No Abstract]   [Full Text] [Related]  

  • 33. National Research Service Awards and Protection of Human Subjects Act.
    Congr Rec (Dly Ed); 1973 Sep; 119(131):S16333-52. PubMed ID: 11663135
    [No Abstract]   [Full Text] [Related]  

  • 34. Beyond localism: a proposal for a National Research Review Board.
    Levine C; Caplan AL
    IRB; 1986; 8(2):7-9. PubMed ID: 11649751
    [No Abstract]   [Full Text] [Related]  

  • 35. Considerations in the protection of humans as subjects of research.
    Chalkley DT
    Bull Pan Am Health Organ; 1974; 8(4):289-92. PubMed ID: 4441729
    [No Abstract]   [Full Text] [Related]  

  • 36. Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989.
    Recomb DNA Tech Bull; 1989 Sep; 12(3):151-70. PubMed ID: 2595016
    [No Abstract]   [Full Text] [Related]  

  • 37. The National Commission on IRBs: an evolutionary approach.
    Veatch RM
    Hastings Cent Rep; 1979 Feb; 9(1):22-8. PubMed ID: 429058
    [No Abstract]   [Full Text] [Related]  

  • 38. Gene treatments for human illness may be tried soon.
    Angier N
    N Y Times Web; 1990 Aug; ():A1, A12. PubMed ID: 11646772
    [No Abstract]   [Full Text] [Related]  

  • 39. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 40. Fears mount for gene scrutiny as watchdog faces axe.
    Kiernan V
    New Sci; 1996 Jun; 150(2033):10. PubMed ID: 11656540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.